ArticleTransfusion2025
Genetic variants in the CD59 gene: An exploratory study of large genome databases.
Article in Transfusion, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genetic variants in the CD59 gene: An exploratory study of large genome databases.Transfusion · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundCD59 is a GPI-anchored glycoprotein on the surface of many cell types. It inhibits the assembly of the membrane attack complex, thus preventing complement-mediated cell lysis. Lack of a functional CD59 protein causes recurrent ischemic strokes, neuropathy, and chronic hemolysis. We aimed at a comprehensive analysis of the CD59 gene from publicly available databases to identify variants and evaluate their pathophysiologic potential.
methodsVariants in the CD59 coding sequence of exons 4, 5, and 6 and their splice sites were systematically compiled from 4 major populations across 6 whole-genome and whole-exome databases. The PredictSNP algorithm assessed the functional impact of non-synonymous variants.
resultsAmong 488,592 individuals, 160 distinct alleles were identified in 6881 subjects (0.7%). Among 93 alleles with non-synonymous variants, 43 were classified as deleterious and 49 (2 variants encoded the same amino acid change) as neutral by PredictSNP. Additional variants included: 53 synonymous, 9 deletions/duplications, 3 splice site, and 2 nonsense. Among the 14 non-synonymous variants reported in patient samples, 9 were classified as deleterious (64.3%) and 5 as neutral (35.7%). DISCUSSION: We collated a list of CD59 variants, which were classified as neutral or deleterious by PredictSNP, from genome databases. These results can be applied to identify individuals with possible latent CD59 deficiency symptoms, such as hemolytic transfusion reactions. In conjunction with clinical data, these CD59 variants can guide personalized clinical decisions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.